Amoebicidal Effect of Fluconazole and Verapamil Together Against Trophozoites and Cysts of Acanthamoeba castellanii

: Acanthamoeba species are important pathogens that causes Acanthamoeba keratitis, which causes a visual loss, as well as central nervous system infection and death by causing encephalitis. Due to the limited available options to successfully treat Acanthamoeba infections, new therapeutic approaches must be developed, and especially combination drug therapy may be a successful and effective strategy. The aim of this study was to assess the combination efficacy of verapamil and fluconazole against Acanthamoeba trophozoites and cysts. The effects of drugs on growth inhibition against Acanthamoeba were tested using amoebicidal assays. The viability of Acanthamoeba was assessed using Trypan blue and hemocytometer counts. The effect of three different concentrations of “fluconazole”, “verapamil” and “fluconazole + verapamil” combination on growth inhibition against Acanthamoeba trophozoites and cysts was significant compared to the control ( p < 0.05 ). While Acanthamoeba reduced the viability of 250 µg/ml fluconazole and verapamil on trophozoites to 2.3 x 10 4 and 3 x 10 4 numbers, fluconazole + verapamil combination showed 100% growth inhibition on trophozoites

[1]  P. Thulasi,et al.  Update on the Management of Acanthamoeba Keratitis , 2022, Current Ophthalmology Reports.

[2]  C. Gunduz,et al.  The Risk Factors and Clinical Features of Acanthamoeba Keratitis: First Time Detection of Acanthamoeba T5 Genotype from Keratitis Patients in Turkey , 2022, Acta Parasitologica.

[3]  K. Megha,et al.  Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium , 2021, Eye.

[4]  T. Tia,et al.  Analysis of Acanthamoeba genotypes from public freshwater sources in Thailand reveals a new genotype, T23 Acanthamoeba bangkokensis sp. nov. , 2021, Scientific Reports.

[5]  A. Huang,et al.  Acanthamoeba Keratitis, Pathology, Diagnosis and Treatment , 2021, Pathogens.

[6]  S. Bonini,et al.  Challenges in Acanthamoeba Keratitis: A Review , 2021, Journal of clinical medicine.

[7]  Ana Gomes de Lacerda,et al.  Acanthamoeba keratitis: a review of biology, pathophysiology and epidemiology , 2020, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[8]  A. Baig,et al.  Targeting CNS Related Protist Pathogens: Calcium Ion Dependency in the Brain-Eating Amoebae. , 2019, ACS chemical neuroscience.

[9]  Zohaib Rana,et al.  Evidence of human‐like Ca2+ channels and effects of Ca2+ channel blockers in Acanthamoeba castellanii , 2019, Chemical biology & drug design.

[10]  A. Baig Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications , 2018, Eye.

[11]  B. Seitz,et al.  Acanthamoeba keratitis – Clinical signs, differential diagnosis and treatment , 2018, Journal of current ophthalmology.

[12]  J. Dart,et al.  Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors , 2018, British Journal of Ophthalmology.

[13]  Ayaz Anwar,et al.  Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole , 2017, Parasitology Research.

[14]  M. Karakuş,et al.  First time identification of Acanthamoeba genotypes in the cornea samples of wild birds; Is Acanthamoeba keratitis making the predatory birds a target? , 2017, Experimental parasitology.

[15]  Y. Hamada,et al.  Evaluation of In Vitro Antiamoebic Activity of Antimicrobial Agents Against Clinical Acanthamoeba Isolates. , 2017, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[16]  D. de Freitas,et al.  Therapeutic agents and biocides for ocular infections by free-living amoebae of Acanthamoeba genus. , 2017, Survey of ophthalmology.

[17]  Payal Gupta,et al.  Antihypertensive, Amlodipine Besilate Inhibits Growth and Biofilm of Human Fungal Pathogen Candida. , 2016, Assay and drug development technologies.

[18]  Liuping Zhang,et al.  Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans , 2016, PloS one.

[19]  J. Lorenzo-Morales,et al.  An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment , 2015, Parasite.

[20]  Qilin Yu,et al.  Inhibitory effect of verapamil on Candida albicans hyphal development, adhesion and gastrointestinal colonization. , 2014, FEMS yeast research.

[21]  Yu Wang,et al.  The Calcium Channel Blocker Verapamil Inhibits Oxidative Stress Response in Candida albicans , 2014, Mycopathologia.

[22]  Ziwen Zhao,et al.  Effects of a combination of amlodipine and imipenem on 42 clinical isolates of Acinetobacter baumannii obtained from a teaching hospital in Guangzhou, China , 2013, BMC Infectious Diseases.

[23]  D. Leonardi,et al.  Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents , 2013, BioMed research international.

[24]  N. Khan,et al.  In Vitro Efficacies of Clinically Available Drugs against Growth and Viability of an Acanthamoeba castellanii Keratitis Isolate Belonging to the T4 Genotype , 2013, Antimicrobial Agents and Chemotherapy.

[25]  F. Schuster,et al.  Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. , 2007, FEMS immunology and medical microbiology.

[26]  N. Khan Acanthamoeba: biology and increasing importance in human health. , 2006, FEMS microbiology reviews.

[27]  G. Cabral,et al.  Acanthamoeba spp. as Agents of Disease in Humans , 2003, Clinical Microbiology Reviews.

[28]  A. Rodrigues,et al.  Inhibition of Germ Tube Formation by Candida albicans by Local Anesthetics: An Effect Related to Ionic Channel Blockade , 2000, Current Microbiology.

[29]  J. Dart,et al.  Risk factors for acanthamoeba keratitis in contact lens users: a case-control study , 1995, BMJ.

[30]  S. Kilvington,et al.  A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. , 1994, Investigative ophthalmology & visual science.

[31]  M. Osato,et al.  In vitro evaluation of antimicrobial compounds for cysticidal activity against Acanthamoeba. , 1991, Reviews of infectious diseases.

[32]  Sonali K Kalra,et al.  Acanthamoeba and its pathogenic role in granulomatous amebic encephalitis. , 2019, Experimental parasitology.

[33]  J. D. de Jonckheere Ecology of Acanthamoeba. , 1991, Reviews of infectious diseases.